Ian J. Griswold, Ph.D.


Ian Griswold, a registered U.S. patent attorney, helps businesses, institutions and organizations translate their ideas into assets. For more than 10 years, Ian has counseled clients on intellectual property matters in the biological and chemical sciences, with a particular emphasis on biotechnology, cancer biology, organic chemistry and pharmaceutical patent prosecution. In addition to patent prosecution, Ian is experienced in preparing opinions on patentability, inventorship, freedom-to-operate, invalidity and non-infringement. He also has experience in inter partes reexamination and interference proceedings.

Ian holds an undergraduate degree in chemistry and a doctorate in molecular biology. Before becoming a lawyer he worked on biological problems in cancer as a post-doctoral research associate at Howard Hughes Medical Institute and the Center for Hematological Malignancies at Oregon Health and Science University (now the Knight Cancer Institute). He determined the transformation potential of various Gleevec®-resistant Bcr-Abl mutations, studied the pharmacokinetics of second generation kinase inhibitors in collaboration with pharmaceutical companies, and developed a retro-virally introduced mouse model of Gleevec®-resistant leukemia.

Ian’s diverse background, ranging from synthetic organic chemistry to translational medicine, gives him a unique perspective on inventions in the chemical and life sciences. His desire for continued learning and challenge reinforces his commitment to understanding all aspects of his clients’ businesses.  



  • 9,157,087, Inducible Plant Promoters and the Use Thereof[LS1] 
  • 9,107,878, Methods of Treating Cancer
  • 9,050,589, Alkene Aziridination
  • 9,032,898, Arrangement for Dynamic Control of Running Trim and List of a Boat
  • 8,932,855, Immune Modulating Exosomes
  • 8,916,590, 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or For Treating or Preventing Ocular Diseases or Conditions Associated With a Pathological Abnormality/Change in the Tissue of the Visual System
  • 8,877,177, Chemokine Containing Apheresis Column and Methods of Use
  • 8,852,581, Treatment of Inflammatory Bowel Disease
  • 8,808,666, Peptides that Specifically Target Amyloid Deposits
  • WO/2015/184016, High-Thoughput Assembly of Genetic Elements
  • WO/2015/168026, Method for Label-Free Image Cytometry
  • WO/2015/120290 Thiol-X Click Foldamers for Polymer Affinity and Catalysis Libraries
  • WO/2015/085194, Enhanced Methods of Ribonucleic Acid Hybridization
  • WO/2015/038743, Novel Anthranilic Amides and the Use Thereof
  • WO/2014/205296, Methods for Shearing and Tagging DNA for Chromatin ‎Immunoprecipitation and Sequencing
  • WO/2014/183122, Methods for Determining Response To A Hypomethylating Agent
  • WO/2014/165723, Enhanced Osteogenic Activity of Daidzein Analogs on Human ‎Mesenchymal Stem Cells
  • WO/2014/160212, Detection of Trace Polar Compounds by Optical Sensors
  • WO/2014/152397, Selective Purification of RNA and RNA-Bound Molecular ‎Complexes
  • WO/2014/152155, Massively Multiplexed RNA Sequencing
  • WO/2014/152643, Microfluidic Microbe Detection and Isolation
  • WO/2014/152281, Ribosomal Ribonucleic Acid Hybridization for Organism ‎Identification
  • WO/2014/144476, Methods for the Detection of DNA-RNA Proximity In Vivo
  • WO/2014/144491, Methods for Determining Multiple Interactions Between Nucleic ‎Acids in a Cell
  • WO/2014/107573, Method for the Determination of Biomolecule Turnover Rates
  • WO/2014/062689, Removable Tattoo Ink and the Use Thereof

Memberships & Awards


  • AUTM
  • Intellectual Property Section, Oregon State Bar

Resources & Ideas

Seminars & Speaking Engagements




Oregon State Courts

United States Patent and Trademark Office

Outside The Office